Last reviewed · How we verify
Diphacil — Competitive Intelligence Brief
phase 2
adiphenine
Histamine H1 receptor, Muscarinic acetylcholine receptor
Other
Small molecule
Live · refreshed every 30 min
Target snapshot
Diphacil (ADIPHENINE). Diphacil is believed to work by modulating certain physiological processes.
Comparator set (1 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Diphacil TARGET | ADIPHENINE | phase 2 | adiphenine | Histamine H1 receptor, Muscarinic acetylcholine receptor | ||
| Celestone Soluspan | betamethasone phosphate | Merck & Co. | marketed | Corticosteroid | Glucocorticoid receptor, Histamine H1 receptor, Muscarinic acetylcholine receptor M1 | 1965-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (adiphenine class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Diphacil CI watch — RSS
- Diphacil CI watch — Atom
- Diphacil CI watch — JSON
- Diphacil alone — RSS
- Whole adiphenine class — RSS
Cite this brief
Drug Landscape (2026). Diphacil — Competitive Intelligence Brief. https://druglandscape.com/ci/adiphenine. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing